UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2019~~2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois Corporation		I.R.S. Employer Identification No.
		36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Shares, Without Par Value		ABT		New York Stock Exchange Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer	☒	Accelerated Filer	☐
Non-Accelerated Filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of September 30, ~~2019,~~2020, Abbott Laboratories had ~~1,768,455,705~~1,772,361,581 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents

	~~Page~~

Part I - Financial Information
	Page
Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings	3
Condensed Consolidated Statement of Comprehensive Income	4
Condensed Consolidated Balance Sheet	5
Condensed Consolidated Statement of Shareholders’ Investment	6
Condensed Consolidated Statement of Cash Flows	8
Notes to the Condensed Consolidated Financial Statements	9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	2118

Item 4. Controls and Procedures	2623

Part II - Other Information

Item 1. Legal Proceedings	2623

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	2723

Item 6. Exhibits	2824

Signature	2925

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)

Three Months Ended September 30

Nine Months Ended September 30


2019

2018

2019

2018
Net sales

$
8,076

$
7,656

$
23,590

$
22,813

Cost of products sold, excluding amortization of intangible assets

3,358

3,166

9,797

9,515
Amortization of intangible assets

484

544

1,453

1,690
Research and development

596

574

1,845

1,738
Selling, general and administrative

2,440

2,377

7,352

7,385
Total operating cost and expenses

6,878

6,661

20,447

20,328

Operating earnings

1,198

995

3,143

2,485

Interest expense

167

203

506

640
Interest (income)

(24)

(22)

(69)

(71)
Net foreign exchange (gain) loss

7

11

9

2
Net loss on extinguishment of debt

—

67

—

81
Other (income) expense, net

(55)

18

(140)

(93)
Earnings from continuing operations before taxes

1,103

718

2,837

1,926
Taxes on earnings from continuing operations

143

166

199

247
Earnings from continuing operations

960

552

2,638

1,679

Earnings from discontinued operations, net of tax

—

11

—

35

Net Earnings

$
960

$
563

$
2,638

$
1,714

Basic Earnings Per Common Share —

Continuing operations

$
0.54

$
0.31

$
1.48

$
0.95
Discontinued operations

—

0.01

—

0.02
Net earnings

$
0.54

$
0.32

$
1.48

$
0.97

Diluted Earnings Per Common Share —

Continuing operations

$
0.53

$
0.31

$
1.47

$
0.94
Discontinued operations

—

0.01

—

0.02
Net earnings

$
0.53

$
0.32

$
1.47

$
0.96

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share

1,771,521

1,759,585

1,767,985

1,757,018
Dilutive Common Stock Options

12,646

12,095

12,818

11,692
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options

1,784,167

1,771,680

1,780,803

1,768,710

Outstanding Common Stock Options Having No Dilutive Effect

61

44

61

44


	Three Months Ended September 30				Nine Months Ended September 30
	2020		2019		2020		2019
Net sales	$	8,853	$	8,076	$	23,907	$	23,590
Cost of products sold, excluding amortization of intangible assets		3,966		3,358		10,510		9,797
Amortization of intangible assets		510		484		1,624		1,453
Research and development		580		596		1,722		1,845
Selling, general and administrative		2,302		2,440		7,126		7,352
Total operating cost and expenses		7,358		6,878		20,982		20,447
Operating earnings		1,495		1,198		2,925		3,143
Interest expense		137		167		410		506
Interest (income)		(10)		(24)		(37)		(69)
Net foreign exchange (gain) loss		(7)		7		(3)		9
Other (income) expense, net		(46)		(55)		(25)		(140)
Earnings from continuing operations before taxes		1,421		1,103		2,580		2,837
Tax expense on earnings from continuing operations		189		143		267		199
Earnings from continuing operations		1,232		960		2,313		2,638

Earnings from discontinued operations, net of tax		—		—		20		—

Net Earnings	$	1,232	$	960	$	2,333	$	2,638

Basic Earnings Per Common Share —
Continuing operations	$	0.69	$	0.54	$	1.30	$	1.48
Discontinued operations		—		—		0.01		—
Net earnings	$	0.69	$	0.54	$	1.31	$	1.48

Diluted Earnings Per Common Share —
Continuing operations	$	0.69	$	0.53	$	1.29	$	1.47
Discontinued operations		—		—		0.01		—
Net earnings	$	0.69	$	0.53	$	1.30	$	1.47

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share		1,774,475		1,771,521		1,772,166		1,767,985
Dilutive Common Stock Options		13,378		12,646		12,381		12,818
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options		1,787,853		1,784,167		1,784,547		1,780,803
Outstanding Common Stock Options Having No Dilutive Effect		—		61		—		61

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)


	Three Months Ended September 30				Nine Months Ended September 30				Three Months Ended September 30				Nine Months Ended September 30
	2019		2018		2019		2018		2020		2019		2020		2019
Net Earnings	$	960	$	563	$	2,638	$	1,714	$	1,232	$	960	$	2,333	$	2,638
Foreign currency translation gain (loss) adjustments		(478)		(153)		(265)		(1,179)		112		(478)		(677)		(265)
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $7 and $21 in 2019 and $16 and $48 in 2018		31		22		80		106
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $23 and $8 in 2019 and $16 and $44 in 2018		49		35		8		121
Other comprehensive (loss)		(398)		(96)		(177)		(952)
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $14 and $42 in 2020 and $7 and $21 in 2019										28		31		122		80
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $(43) and $(24) in 2020 and $23 and $8 in 2019										(104)		49		(24)		8
Other comprehensive income (loss)										36		(398)		(579)		(177)
Comprehensive Income	$	562	$	467	$	2,461	$	762	$	1,268	$	562	$	1,754	$	2,461


	September 30,		December 31,		September 30,		December 31,
	2019		2018		2020		2019
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	$	(5,177)	$	(4,912)	$	(5,601)	$	(4,924)
Net actuarial (losses) and prior service (costs) and credits		(2,646)		(2,726)		(3,418)		(3,540)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other		60		52		(25)		(1)
Accumulated other comprehensive income (loss)	$	(7,763)	$	(7,586)	$	(9,044)	$	(8,465)

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)


		September 30,		December 31,
	2020		2019
Assets
Current Assets:
Cash and cash equivalents	$	4,480	$	3,860
Short-term investments		251		280
Trade receivables, less allowances of $446 in 2020 and $384 in 2019		5,649		5,425
Inventories:
Finished products		3,173		2,784
Work in process		721		560
Materials		1,258		972
Total inventories		5,152		4,316
Prepaid expenses and other receivables		1,858		1,786
Total Current Assets		17,390		15,667
Investments		803		883
Property and equipment, at cost		17,972		16,799
Less: accumulated depreciation and amortization		9,352		8,761
Net property and equipment		8,620		8,038
Intangible assets, net of amortization		15,208		17,025
Goodwill		23,338		23,195
Deferred income taxes and other assets		3,684		3,079
	$	69,043	$	67,887


	September 30,		December 31,
	2019		2018
Assets
Current Assets:
Cash and cash equivalents	$	4,091	$	3,844
Short-term investments		244		242
Trade receivables, less allowances of $354 in 2019 and $314 in 2018		5,450		5,182
Inventories:
Finished products		2,846		2,407
Work in process		584		499
Materials		962		890
Total inventories		4,392		3,796
Prepaid expenses and other receivables		1,942		1,568
Total Current Assets		16,119		14,632
Investments		874		897
Property and equipment, at cost		16,343		15,706
Less: accumulated depreciation and amortization		8,518		8,143
Net property and equipment		7,825		7,563
Intangible assets, net of amortization		17,465		18,942
Goodwill		23,046		23,254
Deferred income taxes and other assets		3,210		1,885
	$	68,539	$	67,173
Liabilities and Shareholders’ Investment
Current Liabilities:
Short-term borrowings	$	204	$	200	$	208	$	201
Trade accounts payable		3,029		2,975		3,189		3,252
Salaries, wages and commissions		1,258		1,182		1,439		1,237
Other accrued liabilities		4,112		3,780		4,659		4,035
Dividends payable		567		563		639		635
Income taxes payable		67		305		117		226
Current portion of long-term debt		1,254		7		6		1,277
Total Current Liabilities		10,491		9,012		10,257		10,863
Long-term debt		17,639		19,359		18,349		16,661
Post-employment obligations, deferred income taxes and other long-term liabilities		8,390		8,080		8,842		9,062
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, 1 dollar par value Authorized — 1,000,000 shares, NaN issued		—		—		—		—
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2019: 1,976,705,285; 2018: 1,971,189,465		23,771		23,512
Common shares held in treasury, at cost — Shares: 2019: 208,249,580; 2018: 215,570,043		(9,631)		(9,962)
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2020: 1,980,767,223; 2019: 1,976,855,085						24,037		23,853
Common shares held in treasury, at cost — Shares: 2020: 208,405,642; 2019: 214,351,838						(9,873)		(10,147)
Earnings employed in the business		25,440		24,560		26,266		25,847
Accumulated other comprehensive income (loss)		(7,763)		(7,586)		(9,044)		(8,465)
Total Abbott Shareholders’ Investment		31,817		30,524		31,386		31,088
Noncontrolling Interests in Subsidiaries		202		198		209		213
Total Shareholders’ Investment		32,019		30,722		31,595		31,301
	$	68,539	$	67,173	$	69,043	$	67,887

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)


	Three Months Ended September 30				Three Months Ended September 30
	2019		2018		2020		2019
Common Shares:
Balance at June 30
Shares: 2019: 1,976,248,129; 2018: 1,969,575,366	$	23,665	$	23,317
Shares: 2020: 1,979,594,379; 2019: 1,976,248,129					$	23,893	$	23,665
Issued under incentive stock programs
Shares: 2019: 457,156; 2018: 1,015,106		18		33
Shares: 2020: 1,172,844; 2019: 457,156						48		18
Share-based compensation		93		83		101		93
Issuance of restricted stock awards		(5)		(5)		(5)		(5)
Balance at September 30
Shares: 2019: 1,976,705,285; 2018: 1,970,590,472	$	23,771	$	23,428
Shares: 2020: 1,980,767,223; 2019: 1,976,705,285					$	24,037	$	23,771

Common Shares Held in Treasury:
Balance at June 30
Shares: 2019: 208,850,514; 2018: 215,256,082	$	(9,659)	$	(9,907)
Shares: 2020: 209,064,380; 2019: 208,850,514					$	(9,904)	$	(9,659)
Issued under incentive stock programs
Shares: 2019: 605,458; 2018: 1,002,519		28		49
Shares: 2020: 664,727; 2019: 605,458						32		28
Purchased
Shares: 2019: 4,524; 2018: 3,877		—		—
Shares: 2020: 5,989; 2019: 4,524						(1)		—
Balance at September 30
Shares: 2019: 208,249,580; 2018: 214,257,440	$	(9,631)	$	(9,858)
Shares: 2020: 208,405,642; 2019: 208,249,580					$	(9,873)	$	(9,631)

Earnings Employed in the Business:
Balance at June 30	$	25,045	$	24,080	$	25,669	$	25,045
Net earnings		960		563		1,232		960
Cash dividends declared on common shares (per share — 2019: $0.32; 2018: $0.28)		(570)		(495)
Cash dividends declared on common shares (per share — 2020: $0.36; 2019: $0.32)						(641)		(570)
Effect of common and treasury share transactions		5		(4)		6		5
Balance at September 30	$	25,440	$	24,144	$	26,266	$	25,440

Accumulated Other Comprehensive Income (Loss):
Balance at June 30	$	(7,365)	$	(6,913)	$	(9,080)	$	(7,365)
Other comprehensive income (loss)		(398)		(96)		36		(398)
Balance at September 30	$	(7,763)	$	(7,009)	$	(9,044)	$	(7,763)

Noncontrolling Interests in Subsidiaries:
Balance at June 30	$	208	$	197	$	220	$	208
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases		(6)		(4)		(11)		(6)
Balance at September 30	$	202	$	193	$	209	$	202

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)


	Nine Months Ended September 30				Nine Months Ended September 30
	2019		2018		2020		2019
Common Shares:
Balance at January 1
Shares: 2019: 1,971,189,465; 2018: 1,965,908,188	$	23,512	$	23,206
Shares: 2020: 1,976,855,085; 2019: 1,971,189,465					$	23,853	$	23,512
Issued under incentive stock programs
Shares: 2019: 5,515,820; 2018: 4,682,284		205		145
Shares: 2020: 3,912,138; 2019: 5,515,820						167		205
Share-based compensation		436		398		451		436
Issuance of restricted stock awards		(382)		(321)		(434)		(382)
Balance at September 30
Shares: 2019: 1,976,705,285; 2018: 1,970,590,472	$	23,771	$	23,428
Shares: 2020: 1,980,767,223; 2019: 1,976,705,285					$	24,037	$	23,771

Common Shares Held in Treasury:
Balance at January 1
Shares: 2019: 215,570,043; 2018: 222,305,719	$	(9,962)	$	(10,225)
Shares: 2020: 214,351,838; 2019: 215,570,043					$	(10,147)	$	(9,962)
Issued under incentive stock programs
Shares: 2019: 7,591,844; 2018: 8,296,855		352		382
Shares: 2020: 6,211,326; 2019: 7,591,844						295		352
Purchased
Shares: 2019: 271,381; 2018: 248,576		(21)		(15)
Shares: 2020: 265,130; 2019: 271,381						(21)		(21)
Balance at September 30
Shares: 2019: 208,249,580; 2018: 214,257,440	$	(9,631)	$	(9,858)
Shares: 2020: 208,405,642; 2019: 208,249,580					$	(9,873)	$	(9,631)

Earnings Employed in the Business:
Balance at January 1	$	24,560	$	23,978	$	25,847	$	24,560
Impact of adoption of new accounting standards		—		15
Impact of adoption of new accounting standard						(5)		—
Net earnings		2,638		1,714		2,333		2,638
Cash dividends declared on common shares (per share — 2019: $0.96; 2018: $0.84)		(1,706)		(1,483)
Cash dividends declared on common shares (per share — 2020: $1.08; 2019: $0.96)						(1,922)		(1,706)
Effect of common and treasury share transactions		(52)		(80)		13		(52)
Balance at September 30	$	25,440	$	24,144	$	26,266	$	25,440

Accumulated Other Comprehensive Income (Loss):
Balance at January 1	$	(7,586)	$	(6,062)	$	(8,465)	$	(7,586)
Impact of adoption of new accounting standard		—		5
Other comprehensive income (loss)		(177)		(952)		(579)		(177)
Balance at September 30	$	(7,763)	$	(7,009)	$	(9,044)	$	(7,763)

Noncontrolling Interests in Subsidiaries:
Balance at January 1	$	198	$	201	$	213	$	198
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases		4		(8)		(4)		4
Balance at September 30	$	202	$	193	$	209	$	202

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(dollars in millions)


	Nine Months Ended September 30				Nine Months Ended September 30
	2019		2018		2020		2019
Cash Flow From (Used in) Operating Activities:
Net earnings	$	2,638	$	1,714	$	2,333	$	2,638
Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation		805		825		837		805
Amortization of intangible assets		1,453		1,690		1,624		1,453
Share-based compensation		434		396		448		434
Amortization of inventory step-up		—		32
Trade receivables		(357)		(280)		(343)		(357)
Inventories		(730)		(450)		(838)		(730)
Other, net		(523)		608		42		(523)
Net Cash From Operating Activities		3,720		4,535		4,103		3,720

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment		(1,204)		(927)		(1,498)		(1,204)
Acquisitions of businesses and technologies, net of cash acquired		(171)		(43)		(32)		(171)
Proceeds from business dispositions		48		48		48		48
Sales (purchases) of other investment securities, net		(22)		(23)		(15)		(22)
Other		23		85		13		23
Net Cash (Used in) Investing Activities		(1,326)		(860)		(1,484)		(1,326)

Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other		52		22		3		52
Proceeds from issuance of long-term debt		—		4,011		1,280		—
Repayments of long-term debt		(523)		(8,279)		(1,332)		(523)
Purchases of common shares		(222)		(134)		(242)		(222)
Proceeds from stock options exercised		291		244		229		291
Dividends paid		(1,702)		(1,479)		(1,919)		(1,702)
Other						(11)		—
Net Cash (Used in) Financing Activities		(2,104)		(5,615)		(1,992)		(2,104)

Effect of exchange rate changes on cash and cash equivalents		(43)		(98)		(7)		(43)

Net Increase (Decrease) in Cash and Cash Equivalents		247		(2,038)
Net Increase in Cash and Cash Equivalents						620		247
Cash and Cash Equivalents, Beginning of Year		3,844		9,407		3,860		3,844
Cash and Cash Equivalents, End of Period	$	4,091	$	7,369	$	4,480	$	4,091

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2019~~2020

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, ~~2018.~~2019. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — New Accounting Standards

Recently Adopted Accounting Standards

In ~~February~~June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) ~~2016-02,~~ ~~Leases~~, which requires lessees to measure and recognize a lease asset and liability on the balance sheet for most leases, including operating leases. Abbott adopted the new standard as of January 1, 2019 using the modified retrospective approach and applied the standard’s transition provisions as of January 1, 2019. As a result, no changes were made to the December 31, 2018 Consolidated Balance Sheet. Abbott elected to apply the package of practical expedients related to transition. These practical expedients allowed Abbott to carry forward its historical assessments of whether any existing contracts are or contain leases, the lease classification for each lease existing at January 1, 2019, and whether any initial direct costs for such leases qualified for capitalization.

The new lease accounting standard does not have a material impact on the amounts reported in the Condensed Consolidated Statement of Earnings but does have a material impact on the amounts reported in the Condensed Consolidated Balance Sheet. Adoption of the new standard resulted in the recording of approximately $850 million of new right of use (ROU) assets and additional liabilities for operating leases on the Condensed Consolidated Balance Sheet as of January 1, 2019.

~~Recent Accounting Standards Not Yet Adopted~~

~~In June 2016, the FASB issued ASU~~ 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative adjustment that was not significant to Earnings employed in the business in the Condensed Consolidated Balance Sheet.

Recent Accounting Standards Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The ~~new~~ standard ~~will be~~becomes effective for Abbott atin the ~~beginning~~first quarter of ~~2020, with~~2021 and early adoption is permitted. Abbott ~~is currently assessing the impact~~does not expect adoption of this new standard to have a material impact on its condensed consolidated financial statements.

Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has 4 reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and ~~Cardiovascular and Neuromodulation Products. Diabetes Care is a non-reportable segment and is included in Other.~~Medical Devices.

The following tables provide detail by sales category:


	Three Months Ended September 30, 2020						Three Months Ended September 30, 2019
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	799	$	799	$	—	$	891	$	891
Other		—		300		300		—		321		321
Total		—		1,099		1,099		—		1,212		1,212

Nutritionals —
Pediatric Nutritionals		488		518		1,006		478		566		1,044
Adult Nutritionals		330		588		918		310		520		830
Total		818		1,106		1,924		788		1,086		1,874

Diagnostics —
Core Laboratory		284		892		1,176		272		905		1,177
Molecular		220		238		458		35		76		111
Point of Care		96		35		131		112		32		144
Rapid Diagnostics		533		342		875		283		194		477
Total		1,133		1,507		2,640		702		1,207		1,909

Medical Devices —
Rhythm Management		242		265		507		265		273		538
Electrophysiology		192		249		441		185		242		427
Heart Failure		144		46		190		136		50		186
Vascular		230		400		630		251		446		697
Structural Heart		159		194		353		158		190		348
Neuromodulation		170		36		206		165		39		204
Diabetes Care		226		617		843		175		490		665
Total		1,363		1,807		3,170		1,335		1,730		3,065

Other		15		5		20		9		7		16

Total	$	3,329	$	5,524	$	8,853	$	2,834	$	5,242	$	8,076

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2019~~2020

(Unaudited)

~~The following tables provide detail by sales category:~~


	Nine Months Ended September 30, 2020						Nine Months Ended September 30, 2019
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	2,376	$	2,376	$	—	$	2,496	$	2,496
Other		—		780		780		—		816		816
Total		—		3,156		3,156		—		3,312		3,312

Nutritionals —
Pediatric Nutritionals		1,490		1,629		3,119		1,406		1,718		3,124
Adult Nutritionals		948		1,644		2,592		915		1,502		2,417
Total		2,438		3,273		5,711		2,321		3,220		5,541

Diagnostics —
Core Laboratory		840		2,312		3,152		793		2,614		3,407
Molecular		429		527		956		113		213		326
Point of Care		278		109		387		334		90		424
Rapid Diagnostics		1,246		719		1,965		881		617		1,498
Total		2,793		3,667		6,460		2,121		3,534		5,655

Medical Devices —
Rhythm Management		655		727		1,382		790		810		1,600
Electrophysiology		476		652		1,128		549		713		1,262
Heart Failure		411		140		551		428		143		571
Vascular		628		1,108		1,736		787		1,349		2,136
Structural Heart		386		508		894		446		578		1,024
Neuromodulation		392		97		489		485		124		609
Diabetes Care		614		1,736		2,350		485		1,348		1,833
Total		3,562		4,968		8,530		3,970		5,065		9,035

Other		30		20		50		26		21		47

Total	$	8,823	$	15,084	$	23,907	$	8,438	$	15,152	$	23,590

Three Months Ended September 30, 2019

Three Months Ended September 30, 2018
(in millions)

U.S.

Int’l

Total

U.S.

Int’l

Total
Established Pharmaceutical Products —












Key Emerging Markets

$
—

$
891

$
891

$
—

$
866

$
866
Other

—

321

321

—

293

293
Total

—

1,212

1,212

—

1,159

1,159

Nutritionals —












Pediatric Nutritionals

478

566

1,044

459

580

1,039
Adult Nutritionals

310

520

830

315

484

799
Total

788

1,086

1,874

774

1,064

1,838

Diagnostics —












Core Laboratory

272

905

1,177

249

837

1,086
Molecular

35

76

111

37

84

121
Point of Care

112

32

144

106

30

136
Rapid Diagnostics

283

194

477

274

207

481
Total

702

1,207

1,909

666

1,158

1,824

Cardiovascular and Neuromodulation —












Rhythm Management

265

273

538

272

261

533
Electrophysiology

185

242

427

169

212

381
Heart Failure

136

50

186

111

41

152
Vascular

251

446

697

284

436

720
Structural Heart

158

190

348

126

179

305
Neuromodulation

165

39

204

172

40

212
Total

1,160

1,240

2,400

1,134

1,169

2,303

Other

184

497

681

133

399

532
Total

$
2,834

$
5,242

$
8,076

$
2,707

$
4,949

$
7,656

Nine Months Ended September 30, 2019

Nine Months Ended September 30, 2018
(in millions)

U.S.

Int’l

Total

U.S.

Int’l

Total
Established Pharmaceutical Products —












Key Emerging Markets

$
—

$
2,496

$
2,496

$
—

$
2,525

$
2,525
Other

—

816

816

—

807

807
Total

—

3,312

3,312

—

3,332

3,332

Nutritionals —












Pediatric Nutritionals

1,406

1,718

3,124

1,376

1,708

3,084
Adult Nutritionals

915

1,502

2,417

937

1,431

2,368
Total

2,321

3,220

5,541

2,313

3,139

5,452

Diagnostics —












Core Laboratory

793

2,614

3,407

725

2,508

3,233
Molecular

113

213

326

114

247

361
Point of Care

334

90

424

324

92

416
Rapid Diagnostics

881

617

1,498

855

669

1,524
Total

2,121

3,534

5,655

2,018

3,516

5,534

Cardiovascular and Neuromodulation —












Rhythm Management

790

810

1,600

843

824

1,667
Electrophysiology

549

713

1,262

499

645

1,144
Heart Failure

428

143

571

342

126

468
Vascular

787

1,349

2,136

854

1,355

2,209
Structural Heart

446

578

1,024

353

560

913
Neuromodulation

485

124

609

513

133

646
Total

3,485

3,717

7,202

3,404

3,643

7,047

Other

511

1,369

1,880

349

1,099

1,448
Total

$
8,438

$
15,152

$
23,590

$
8,084

$
14,729

$
22,813

Note: Insertable Cardiac Monitor (ICM) sales, which had previously been reported in Electrophysiology, are now included in Rhythm Management. Historic periods have been adjusted to reflect this change.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

Remaining Performance Obligations

As of September 30, ~~2019,~~2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately ~~$3.2~~$3.6 billion in the Diagnostics segment and approximately ~~$350~~$430 million in the ~~Cardiovascular and Neuromodulation~~Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 1618 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at ~~their~~the net ~~realizable value.~~amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the ~~Cardiovascular and Neuromodulation~~Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)

Contract Liabilities:

Balance at December 31, 2018

$
259
Unearned revenue from cash received during the period

285
Revenue recognized that was included in contract liability balance at beginning of period

(249)
Balance at September 30, 2019

$
295


(in millions)
Contract Liabilities
Balance at December 31, 2019	$	294
Unearned revenue from cash received during the period		350
Revenue recognized related to contract liability balance		(293)
Balance at September 30, 2020	$	351

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2020

(Unaudited)

Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended September 30, 2020 and 2019 were $1.226 billion and ~~2018 were~~ $954 ~~million and $548~~ million, respectively, and for the nine months ended September 30, 2020 and 2019 ~~and 2018~~ were ~~$2.622~~$2.302 billion and ~~$1.669~~$2.622 billion, respectively. Net earnings allocated to common shares for the three months ended September 30, 2020 and 2019 were $1.226 billion and ~~2018 were~~ $954 ~~million and $560~~ million, respectively, and for the nine months ended September 30, 2020 and 2019 were $2.322 billion and ~~2018 were~~ $2.622 billion, ~~and $1.704 billion,~~ respectively.

Earnings from discontinued operations, net of tax, in the first nine months of 2020 include the recognition of $20 million of tax benefits as a result of the resolution of various tax positions related to the previous sale of a business that was reported as a discontinued operation.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2020 includes $350 million of pension contributions and the payment of cash taxes of approximately $700 million. The first nine months of 2019 includes $337 million of pension contributions and the payment of cash taxes of approximately $775 million.

The following summarizes the activity for the first nine months of ~~2018 includes the favorable impact of improvements in working capital management, as well as the effect of non-cash charges~~2020 related to the ~~impairment~~allowance for doubtful accounts as of ~~certain assets~~September 30, 2020:


(in millions)
Allowance for Doubtful Accounts
Balance at December 31, 2019	$	228
Impact of adopting ASU 2016-13		7
Provisions/charges to income		63
Amounts charged off and other deductions		(14)
Balance at September 30, 2020	$	284

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the ~~accrual~~aging of ~~certain debt extinguishment costs.~~the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.

The components of long-term investments as of September 30, ~~2019~~2020 and December 31, ~~2018~~2019 are as follows:


	September 30,		December 31,		September 30,		December 31,
(in millions)	2019		2018		2020		2019
Long-term Investments:
Long-term Investments
Equity securities	$	830	$	856	$	755	$	836
Other		44		41		48		47
Total	$	874	$	897	$	803	$	883

~~Table~~Abbott’s long-term investments as of ~~Contents~~September 30, 2020 declined versus the balance as of December 31, 2019 due to investment impairments totaling approximately $110 million, recorded in Other (income) expense, net within the Condensed Consolidated Statement of Earnings, which was partially offset by approximately $30 million of additional investments during the first nine months of 2020.

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

Abbott's equity securities as of September 30, ~~2019,~~2020 include approximately ~~$330~~$336 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of September 30, ~~2019~~2020 with a carrying value of approximately ~~$335~~$292 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately ~~$155~~$112 million that do not have a readily determinable fair value. The ~~$155~~$112 million carrying value ~~includes cumulative~~is net of an approximately $60 million impairment of an investment in the second quarter of 2020 for which Abbott had previously recorded an unrealized ~~gains~~gain of approximately $50 ~~million.~~million in 2018.

In the first quarter of 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired a research & development (R&D) asset valued at $102 million, which was immediately expensed. The $102 million of expense was recorded in the R&D line of Abbott's Condensed Consolidated Statement of Earnings.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2020

(Unaudited)

Note 5 — Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:


																	Three Months Ended September 30
	Three Months Ended September 30																								Cumulative Gains
													Cumulative Gains												(Losses) on
									Cumulative				(Losses) on								Net Actuarial				Derivative
					Net Actuarial				Unrealized Gains				Derivative				Cumulative Foreign				(Losses) and Prior				Instruments
	Cumulative Foreign				(Losses) and Prior				(Losses) on				Instruments				Currency Translation				Service (Costs)				Designated as
	Currency Translation				Service (Costs)				Marketable Equity				Designated as				Adjustments				and Credits				Cash Flow Hedges
(in millions)	Adjustments				and Credits				Securities				Cash Flow Hedges				2020		2019		2020		2019		2020		2019
	2019		2018		2019		2018		2019		2018		2019		2018
Balance at June 30	$	(4,699)	$	(4,478)	$	(2,677)	$	(2,437)	$	—	$	—	$	11	$	2	$	(5,713)	$	(4,699)	$	(3,446)	$	(2,677)	$	79	$	11
Other comprehensive income (loss) before reclassifications		(478)		(153)		7		—		—		—		67		10		112		(478)		(21)		7		(74)		67
Amounts reclassified from accumulated other comprehensive income		—		—		24		22		—		—		(18)		25		—		—		49		24		(30)		(18)
Net current period comprehensive income (loss)		(478)		(153)		31		22		—		—		49		35		112		(478)		28		31		(104)		49
Balance at September 30	$	(5,177)	$	(4,631)	$	(2,646)	$	(2,415)	$	—	$	—	$	60	$	37	$	(5,601)	$	(5,177)	$	(3,418)	$	(2,646)	$	(25)	$	60


																	Nine Months Ended September 30
	Nine Months Ended September 30																								Cumulative Gains
													Cumulative Gains												(Losses) on
									Cumulative				(Losses) on								Net Actuarial				Derivative
					Net Actuarial				Unrealized Gains				Derivative				Cumulative Foreign				(Losses) and Prior				Instruments
	Cumulative Foreign				(Losses) and Prior				(Losses) on				Instruments				Currency Translation				Service (Costs)				Designated as
	Currency Translation				Service (Costs)				Marketable Equity				Designated as				Adjustments				and Credits				Cash Flow Hedges
(in millions)	Adjustments				and Credits				Securities				Cash Flow Hedges				2020		2019		2020		2019		2020		2019
	2019		2018		2019		2018		2019		2018		2019		2018
Balance at December 31 , 2018 and 2017	$	(4,912)	$	(3,452)	$	(2,726)	$	(2,521)	$	—	$	(5)	$	52	$	(84)
Impact of adoption of new accounting standard		—		—		—		—		—		5		—		—
Balance at January 1																	$	(4,924)	$	(4,912)	$	(3,540)	$	(2,726)	$	(1)	$	52
Other comprehensive income (loss) before reclassifications		(265)		(1,179)		9		—		—		—		48		38		(677)		(265)		(23)		9		35		48
Amounts reclassified from accumulated other comprehensive income		—		—		71		106		—		—		(40)		83		—		—		145		71		(59)		(40)
Net current period comprehensive income (loss)		(265)		(1,179)		80		106		—		—		8		121		(677)		(265)		122		80		(24)		8
Balance at September 30	$	(5,177)	$	(4,631)	$	(2,646)	$	(2,415)	$	—	$	—	$	60	$	37	$	(5,601)	$	(5,177)	$	(3,418)	$	(2,646)	$	(25)	$	60

Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange (gain) ~~loss~~loss; and amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 1312 for additional details.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

Note 6 — Goodwill and Intangible Assets

The total amount of goodwill reported was ~~$23.0~~$23.3 billion at September 30, ~~2019~~2020 and ~~$23.3~~$23.2 billion at December 31, ~~2018.~~2019. Foreign currency translation adjustments ~~decreased~~increased goodwill by approximately ~~$252~~$144 million ~~during~~in the first nine months of ~~2019.~~2020. The amount of goodwill related to reportable segments at September 30, ~~2019~~2020 was ~~$3.0~~$2.9 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.7 billion for the Diagnostic Products segment, and ~~$15.2~~$16.4 billion for the ~~Cardiovascular and Neuromodulation Products~~Medical Devices segment. There was 0 reduction of goodwill relating to impairments in the first nine months of ~~2019.~~2020.

The gross amount of amortizable intangible assets, primarily product rights and technology, was ~~$25.1~~$27.5 billion as of September 30, ~~2019~~2020 and ~~$25.7~~$27.6 billion as of December 31, ~~2018,~~2019, and accumulated amortization was ~~$11.2~~$13.5 billion as of September 30, ~~2019~~2020 and ~~$10.4~~$11.9 billion as of December 31, ~~2018.~~2019. Foreign currency translation adjustments decreased intangible assets by ~~approximately $110~~$69 million ~~during~~in the first nine months of ~~2019.~~2020. An asset impairment related to the Medical Devices segment decreased intangible assets by $148 million in the third quarter and first nine months of 2020. The impairment was recorded in the Cost of products sold, excluding amortization of intangible assets line of Abbott's Condensed Consolidated Statement of Earnings. Abbott’s estimated annual amortization expense for intangible assets is approximately ~~$1.9 billion in 2019,~~ $2.1 billion in 2020, $2.0 billion per year in 2021, ~~$2.0~~2022, and 2023 and $1.9 billion in ~~2022 and $2.0 billion in 2023.~~2024.

Indefinite-lived intangible assets, which relate to in-process ~~research and development~~R&D acquired in a business combination, were approximately ~~$3.6~~$1.2 billion and $1.3 billion as of September 30, ~~2019~~2020 and December 31, ~~2018~~2019, respectively.

Note 7 — Restructuring Plans

From 2017 to ~~2019,~~2020, Abbott management approved restructuring plans as part of the integration of the acquisitions of St. Jude Medical into the ~~Cardiovascular and Neuromodulation~~Medical Devices segment, and Alere Inc. (Alere) into the ~~Diagnostics~~Diagnostic Products segment, in order to leverage economies of scale and reduce costs. In the first nine months of ~~2019,~~2020, charges of ~~$66~~$13 million were recognized, of which ~~$18~~$6 million is recorded in Cost of products sold, $4$1 million is recorded in Research and development and ~~$44~~$6 million as Selling, general and administrative expense. The following summarizes the activity for the first nine months of ~~2019~~2020 related to these actions and the status of the related accrual as of September 30, ~~2019:~~2020:

(in millions)

Accrued balance at December 31, 2018

$
41
Restructuring charges recorded in 2019

66
Payments and other adjustments

(45)
Accrued balance at September 30, 2019

$
62


(in millions)
Accrued balance at December 31, 2019	$	46
Restructuring charges recorded in 2020		13
Payments and other adjustments		(24)
Accrued balance at September 30, 2020	$	35

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2020

(Unaudited)

From ~~2016~~2017 to ~~2019,~~2020, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. In the first nine months of ~~2019,~~2020, charges of ~~$35~~$29 million were recognized, of which ~~$10~~$1 million is recorded in Cost of products sold, $8$1 million is recorded in Research and development and ~~$17~~$27 million as Selling, general and administrative expense. The following summarizes the activity for the first nine months of ~~2019~~2020 related to these restructuring actions and the status of the related accrual as of September 30, ~~2019:~~2020:


(in millions)
Accrued balance at December 31, 2018	$	70
Restructuring charges recorded in 2019		35
Accrued balance at December 31, 2019			$	79
Restructuring charges recorded in 2020				29
Payments and other adjustments		(29)		(24)
Accrued balance at September 30, 2019	$	76
Accrued balance at September 30, 2020			$	84

Note 8 — Incentive Stock Programs

In the first nine months of ~~2019,~~2020, Abbott granted ~~4,579,283~~4,006,336 stock options, ~~736,100~~568,471 restricted stock awards and ~~6,568,376~~5,183,375 restricted stock units under its current incentive stock ~~programs.~~program. At September 30, ~~2019,~~2020, approximately ~~126~~113 million common shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September 30, ~~2019~~2020 is as follows:


	Outstanding		Exercisable		Outstanding		Exercisable
Number of shares		30,219,778		20,793,077		29,352,400		20,764,950
Weighted average remaining life (years)		6.5		5.5		6.2		5.2
Weighted average exercise price	$	48.65	$	41.13	$	55.34	$	45.92
Aggregate intrinsic value (in millions)	$	1,058	$	885	$	1,570	$	1,306

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

The total unrecognized share-based compensation cost at September 30, ~~2019~~2020 amounted to approximately ~~$501~~$499 million which is expected to be recognized over the next three years.

Note 9 — Debt and Lines of Credit

On September 28, 2020, Abbott repaid the €1.140 billion outstanding principal amount of its 0.00% Notes due 2020 upon maturity. The repayment equated to approximately $1.3 billion.

On June 24, 2020, Abbott completed the issuance of $1.3 billion aggregate principal amount of senior notes, consisting of $650 million of its 1.15% Notes due 2028 and $650 million of its 1.40% Notes due 2030.

On February 24, 2019, Abbott redeemed the $500 million outstanding principal amount of its 2.80% Notes due 2020.

~~In September 2019, the board of directors authorized the early redemption of up to $5billion of outstanding long-term notes. This bond redemption authorization supersedes the board's previous authorization under which $700 million had not yet been redeemed.~~

~~Note 10 — Leases~~

~~Leases where Abbott is the Lessee~~

Abbott has entered into operating leases as the lessee for office space, manufacturing facilities, R&D laboratories, warehouses, vehicles and equipment. Finance leases are not significant. Abbott’s operating leases generally have remaining lease terms of 1 toNote 10 years. Some leases include options to extend beyond the original lease term, generally up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised.

For all of its asset classes, Abbott elected the practical expedient allowed under FASB ASC No. 842, “Leases” to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. Abbott also elected the short-term lease accounting policy for all asset classes; therefore, Abbott is not recognizing a lease liability or ROU asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that Abbott is reasonably certain to exercise.

As Abbott’s leases typically do not provide an implicit rate, the interest rate used to determine the present value of the payments under each lease typically reflects Abbott’s incremental borrowing rate based on information available at the lease commencement date. Abbott’s incremental borrowing rates at January 1, 2019 were used for operating leases that commenced prior to January 1, 2019.

~~The following table provides information related to Abbott’s operating leases:~~

Three Months Ended

Nine Months Ended
(in millions)

September 30, 2019

September 30, 2019
Operating lease cost (a)

$
79

$
233
Cash paid for amounts included in the measurement of operating lease liabilities

$
64

$
190
ROU assets arising from entering into new operating lease obligations

$
104

$
201

~~(a)~~

~~Includes short-term lease expense and variable lease costs, which were immaterial in the three and nine months ended September 30, 2019.~~

~~The weighted average remaining lease term and discount rate for operating leases as of September 30, 2019 were 8 years and 4.1%, respectively.~~

~~Future minimum lease payments under non-cancellable operating leases as of September 30, 2019 were as follows:~~

(in millions)

2019

$
61
2020

225
2021

177
2022

137
2023

98
Thereafter

380
Total future minimum lease payments – undiscounted

1,078
Less: imputed interest

(174)
Present value of lease liabilities

$
904

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

~~The following table summarizes the amounts and location of operating lease ROU assets and lease liabilities as of September 30, 2019:~~

(in millions)

September 30, 2019

Balance Sheet Caption

Operating Lease - ROU Asset

$
881

Deferred income taxes and other assets

Operating Lease Liability:





Current

$
202

Other accrued liabilities
Non-current

702

Post-employment obligations, deferred income taxes and other long-term liabilities
Total Liability

$
904

~~Leases where Abbott is the Lessor~~

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Operating lease revenue represented less than 3 percent of Abbott’s total net sales in the three and nine months ended September 30, 2019.

Assets related to operating leases are reported within Net property and equipment on the Condensed Consolidated Balance Sheet. The original cost and the net book value of such assets were $2.7 billion and $1.1 billion, respectively, as of September 30, 2019.

~~Note 11~~ — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in ~~foreign~~ exchange ratesprimarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling ~~$6.3~~$7.9 billion at September 30, ~~2019~~2020 and ~~$5.1~~$6.8 billion at December 31, ~~2018~~2019, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value.Accumulated gains and losses as of September 30, ~~2019 on contracts related to intercompany purchases~~2020 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, ~~2019~~2020 and December 31, ~~2018,~~2019, Abbott held the gross notional amount of ~~$10.4~~$8.9 billion and ~~$13.6~~$9.1 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $566 million and $546 million as of September 30, 2020 and December 31, 2019, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling approximately $2.9 billion at September 30, ~~2019~~2020 and December 31, ~~2018~~2019 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

1513

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2019~~

~~(Unaudited)~~

~~The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2019 and December 31, 2018:~~

Fair Value - Assets

Fair Value - Liabilities

Sept. 30,

Dec. 31,

Sept. 30,

Dec. 31,

(in millions)

2019

2018

Balance Sheet Caption

2019

2018

Balance Sheet Caption

Interest rate swaps designated as fair value hedges

$
74

$
—

Deferred income taxes and other assets

$
—

$
100

Post-employment obligations, deferred income taxes and other long-term liabilities

Foreign currency forward exchange contracts:

Hedging instruments

244

81

Prepaid expenses and other receivables

33

44

Other accrued liabilities
Others not designated as hedges

54

33

Prepaid expenses and other receivables

62

51

Other accrued liabilities

$
372

$
114

$
95

$
195

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2019 and 2018.

Gain (loss) Recognized in Other

Income (expense) and Gain (loss)

Comprehensive Income (loss)

Reclassified into Income

Three Months

Nine Months

Three Months

Nine Months

Ended Sept. 30

Ended Sept. 30

Ended Sept. 30

Ended Sept. 30

Income Statement
(in millions)

2019

2018

2019

2018

2019

2018

2019

2018

Caption

Foreign currency forward exchange contracts designated as cash flow hedges

$
99

$
18

$
78

$
45

$
26

$
(37)

$
58

$
(120)

Cost of products sold

Interest rate swaps designated as fair value hedges

n/a

n/a

n/a

n/a

35

(42)

174

(179)

Interest expense

Gains of $49 million and losses of $10 million were recognized in the three months ended September 30, 2019 and 2018, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $124 million and losses of $60 million were recognized in the nine months ended September 30, 2019 and 2018, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~2020

(Unaudited)

The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2020 and December 31, 2019:


	Fair Value - Assets					Fair Value - Liabilities
	Sept. 30,		Dec. 31,			Sept. 30,		Dec. 31,
(in millions)	2020		2019		Balance Sheet Caption	2020		2019		Balance Sheet Caption
Interest rate swaps designated as fair value hedges	$	232	$	48	Deferred income taxes and other assets	$	—	$	—	Post-employment obligations, deferred income taxes and other long-term liabilities
Foreign currency forward exchange contracts:
Hedging instruments		89		110	Prepaid expenses and other receivables		241		56	Other accrued liabilities
Others not designated as hedges		37		38	Prepaid expenses and other receivables		62		33	Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary		—		—	n/a		566		546	Long-term debt
	$	358	$	196		$	869	$	635


	Gain (loss) Recognized in Other								Income (expense) and Gain (loss)
	Comprehensive Income (loss)								Reclassified into Income
	Three Months				Nine Months				Three Months				Nine Months
	Ended Sept. 30				Ended Sept. 30				Ended Sept. 30				Ended Sept. 30
(in millions)	2020		2019		2020		2019		2020		2019		2020		2019		Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges	$	103	$	99	$	(35)	$	78	$	48	$	26	$	90	$	58	Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary		(10)		—		(20)		—		—		—		—		—	n/a
Interest rate swaps designated as fair value hedges		n/a		n/a		n/a		n/a		(11)		35		184		174	Interest expense

Losses of $100 million and gains of $49 million were recognized in the three months ended September 30, 2020 and 2019, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Losses of $198 million and gains of $124 million were recognized in the nine months ended September 30, 2020 and 2019, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of September 30, ~~2019~~2020 and December 31, ~~2018~~2019 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from ~~nonperformance~~non-performance by these counterparties.


	September 30, 2019				December 31, 2018				September 30, 2020				December 31, 2019
	Carrying		Fair		Carrying		Fair		Carrying		Fair		Carrying		Fair
(in millions)	Value		Value		Value		Value		Value		Value		Value		Value

Investment Securities:
Long-term Investment Securities:
Equity securities	$	830	$	830	$	856	$	856	$	755	$	755	$	836	$	836
Other		44		44		41		41		48		48		47		47
Total Long-term Debt		(18,893)		(21,525)		(19,366)		(19,871)		(18,355)		(22,224)		(17,938)		(20,772)
Foreign Currency Forward Exchange Contracts:
Receivable position		298		298		114		114		126		126		148		148
(Payable) position		(95)		(95)		(95)		(95)		(303)		(303)		(89)		(89)
Interest Rate Hedge Contracts:
Receivable position		74		74		—		—		232		232		48		48
(Payable) position		—		—		(100)		(100)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2020

(Unaudited)

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:


			Basis of Fair Value Measurement								Basis of Fair Value Measurement
			Quoted		Significant						Quoted		Significant
			Prices in		Other		Significant				Prices in		Other		Significant
	Outstanding		Active		Observable		Unobservable		Outstanding		Active		Observable		Unobservable
(in millions)	Balances		Markets		Inputs		Inputs		Balances		Markets		Inputs		Inputs
September 30, 2019:
September 30, 2020:
Equity securities	$	341	$	341	$	—	$	—	$	351	$	351	$	—	$	—
Interest rate swap derivative financial instruments		74		—		74		—		232		—		232		—
Foreign currency forward exchange contracts		298		—		298		—		126		—		126		—
Total Assets	$	713	$	341	$	372	$	—	$	709	$	351	$	358	$	—

Fair value of hedged long-term debt	$	2,927	$	—	$	2,927	$	—	$	3,070	$	—	$	3,070	$	—
Foreign currency forward exchange contracts		95		—		95		—		303		—		303		—
Contingent consideration related to business combinations		68		—		—		68		68		—		—		68
Total Liabilities	$	3,090	$	—	$	3,022	$	68	$	3,441	$	—	$	3,373	$	68

December 31, 2018:
December 31, 2019:
Equity securities	$	320	$	320	$	—	$	—	$	357	$	357	$	—	$	—
Interest rate swap derivative financial instruments										48		—		48		—
Foreign currency forward exchange contracts		114		—		114		—		148		—		148		—
Total Assets	$	434	$	320	$	114	$	—	$	553	$	357	$	196	$	—

Fair value of hedged long-term debt	$	2,743	$	—	$	2,743	$	—	$	2,890	$	—	$	2,890	$	—
Interest rate swap derivative financial instruments		100		—		100		—
Foreign currency forward exchange contracts		95		—		95		—		89		—		89		—
Contingent consideration related to business combinations		71		—		—		71		68		—		—		68
Total Liabilities	$	3,009	$	—	$	2,938	$	71	$	3,047	$	—	$	2,979	$	68

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow ~~analysis. The fair value of foreign currency forward exchange contracts is determined~~analysis using ~~a market approach, which utilizes values for comparable derivative instruments.~~significant other observable inputs. The fair value of the contingent consideration was determined based on an independent ~~appraisal~~appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

Note 1211 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately ~~$110~~$85 million to ~~$140~~$120 million. The recorded accrual balance at September 30, ~~2019~~2020 for these proceedings and exposures was approximately ~~$125~~$105 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 1312 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized in continuing operations for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:


																	Defined Benefit Plans								Medical and Dental Plans
	Defined Benefit Plans								Medical and Dental Plans								Three Months				Nine Months				Three Months				Nine Months
	Three Months				Nine Months				Three Months				Nine Months				Ended September 30				Ended September 30				Ended September 30				Ended September 30
(in millions)	Ended September 30				Ended September 30				Ended September 30				Ended September 30				2020		2019		2020		2019		2020		2019		2020		2019
	2019		2018		2019		2018		2019		2018		2019		2018
Service cost - benefits earned during the period	$	63	$	76	$	188	$	221	$	5	$	7	$	17	$	20
Service cost — benefits earned during the period																	$	85	$	63	$	251	$	188	$	12	$	5	$	35	$	17
Interest cost on projected benefit obligations		84		77		253		232		13		12		39		36		75		84		224		253		11		13		32		39
Expected return on plan assets		(177)		(169)		(533)		(511)		(6)		(9)		(20)		(25)		(193)		(177)		(576)		(533)		(7)		(6)		(21)		(20)
Net amortization of:
Actuarial loss, net		33		51		99		154		6		8		17		25		64		33		191		99		5		6		15		17
Prior service cost (credit)		—		—		1		1		(8)		(11)		(24)		(34)		—		—		1		1		(7)		(8)		(21)		(24)
Net cost - continuing operations	$	3	$	35	$	8	$	97	$	10	$	7	$	29	$	22	$	31	$	3	$	91	$	8	$	14	$	10	$	40	$	29

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2020

(Unaudited)

Abbott funds its domestic defined benefit plans according to ~~IRS~~Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2020 and 2019, ~~and 2018, $337~~$350 million and ~~$71~~$337 million, respectively, were contributed to defined benefit plans and $11 million was contributed to the post-employment medical and dental ~~benefit~~ plans in each year.

Note 1413 — Taxes on Earnings

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2020, taxes on earnings from continuing operations include approximately $81 million in tax benefits related to the settlement of the former St. Jude Medical consolidated group’s 2014 through 2016 federal income tax returns in the U.S. and $87 million in excess tax benefits associated with share-based compensation. Earnings from discontinued operations, net of tax, in the first nine months of 2020 reflect the recognition of $20 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. In the first nine months of 2019, taxes on earnings from continuing operations include a $78 million reduction to the transition tax related to the Tax Cut and Jobs Act (TCJA) and approximately $95 million in excess tax benefits associated with share-based compensation. The $78 million reduction to the transition tax liability was the result of the issuance of final transition tax regulations by the U.S. Department of Treasury in the first ~~quarter. This adjustment decreased the cumulative net tax expense related to the TCJA to $1.51 billion. In the first nine months~~quarter of 2018, taxes on earnings from continuing operations include approximately $80 million in excess tax benefits associated with share-based compensation and a $53 million adjustment to the transition tax liability for associated effects related to state tax. Earnings from discontinued operations, net of tax, in the first nine months of 2018 reflect the recognition of $40 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years which decreased the gross amount of unrecognized tax benefits by $47 million.2019.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease between ~~$185~~$70 million and ~~$430~~$410 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2016 are settled except for the federal income tax returns of the former Alere consolidated group which are settled through ~~2014 and the former St. Jude Medical consolidated group which are settled through 2013.~~2015.

Note 1514 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

~~Cardiovascular and Neuromodulation Products~~Medical Devices — Worldwide sales of ~~cardiac~~ rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and ~~neuromodulation~~diabetes care products. For segment reporting purposes, the Cardiac ~~Arrhythmias &~~Rhythm Management, Electrophysiology and Heart Failure, Vascular, Neuromodulation, ~~and~~ Structural Heart and Diabetes Care divisions are aggregated and reported as the ~~Cardiovascular and Neuromodulation~~Medical Devices segment.

~~Non-reportable segments include Diabetes Care.~~

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

1916

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2019~~2020

(Unaudited)


	Net Sales to External Customers								Operating Earnings								Net Sales to External Customers								Operating Earnings
	Three Months				Nine Months				Three Months				Nine Months				Three Months				Nine Months				Three Months				Nine Months
	Ended September 30				Ended September 30				Ended September 30				Ended September 30				Ended September 30				Ended September 30				Ended September 30				Ended September 30
(in millions)	2019		2018		2019		2018		2019		2018		2019		2018		2020		2019		2020		2019		2020		2019		2020		2019
Established Pharmaceutical Products	$	1,212	$	1,159	$	3,312	$	3,332	$	281	$	289	$	654	$	664	$	1,099	$	1,212	$	3,156	$	3,312	$	201	$	281	$	588	$	654
Nutritional Products		1,874		1,838		5,541		5,452		414		435		1,241		1,224		1,924		1,874		5,711		5,541		394		414		1,327		1,241
Diagnostic Products		1,909		1,824		5,655		5,534		456		443		1,356		1,375		2,640		1,909		6,460		5,655		875		456		1,802		1,356
Cardiovascular and Neuromodulation Products		2,400		2,303		7,202		7,047		741		730		2,179		2,215
Medical Devices																		3,170		3,065		8,530		9,035		928		958		2,122		2,722
Total Reportable Segments		7,395		7,124		21,710		21,365		1,892		1,897		5,430		5,478		8,833		8,060		23,857		23,543		2,398		2,109		5,839		5,973
Other		681		532		1,880		1,448										20		16		50		47
Net sales	$	8,076	$	7,656	$	23,590	$	22,813									$	8,853	$	8,076	$	23,907	$	23,590
Corporate functions and benefit plan costs										(131)		(143)		(332)		(435)										(129)		(131)		(367)		(332)
Non-reportable segments										220		148		547		365
Net interest expense										(143)		(181)		(437)		(569)										(127)		(143)		(373)		(437)
Share-based compensation (a)										(94)		(83)		(434)		(396)										(100)		(94)		(448)		(434)
Amortization of intangible assets										(484)		(544)		(1,453)		(1,690)										(510)		(484)		(1,624)		(1,453)
Other, net (b)										(157)		(376)		(484)		(827)										(111)		(154)		(447)		(480)
Earnings from continuing operations before taxes									$	1,103	$	718	$	2,837	$	1,926									$	1,421	$	1,103	$	2,580	$	2,837

(a)	Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

Other, net for the three and nine months ended September 30, 2020 and 2019 ~~and 2018~~ includes ~~restructuring charges and~~ integration costs associated with the ~~acquisitions~~acquisition of St. Jude Medical and ~~Alere.~~Alere, and restructuring charges. Other, net for the three and nine months ended September 30, 2020 also includes costs related to asset impairments, partially offset by income from the settlement of litigation. Other, net for the nine months ended September 30, 2019 includes charges associated with R&D assets acquired and immediately expensed. ~~Other, net for the nine months ended September 30, 2018 includes inventory step-up amortization.~~

2017

Table of Contents

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review - Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract ~~most~~ impact which products are sold; price controls, competition and rebates ~~most~~ impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are ~~nutritional products, branded generic pharmaceuticals,~~medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.

During the first nine months of 2020, the coronavirus (COVID-19) pandemic affected Abbott’s diversified health care businesses in various ways. As is further described below, some businesses have performed at the levels required to successfully meet new demands, others have faced challenges, and still others have been relatively stable. Beginning in February, cardiovascular and neuromodulation ~~products.~~procedures and routine core laboratory diagnostic testing volumes declined in China as that country implemented quarantine restrictions and postponed non-emergency health care activities. As March progressed, procedures and routine testing volumes in China steadily improved from the low levels seen in February.

As COVID-19 spread geographically, the impact initially expanded to certain countries in Asia and Europe beginning in late February, and more broadly across Europe and the U.S. during March and April. As the health care systems in these countries shifted their focus to fighting COVID-19, the impact on cardiovascular and neuromodulation device procedures and routine diagnostic testing volumes was similar to what was experienced in China in February. COVID-19 affected developed markets most significantly in the second quarter and expanded into key emerging markets in the third quarter. As a result, as is further described below, some businesses slowed and sales of cardiovascular and neuromodulation devices and routine diagnostic tests declined during the first nine months of 2020 from the prior year. Encouragingly, routine testing and procedure volume improved across Abbott’s hospital-based businesses as the second quarter progressed and the improvement continued in the third quarter as both demand for procedures and availability of health care resources return to more normal levels.

Abbott mobilized its teams across multiple fronts to develop and launch nine new diagnostic tests for COVID-19:

●

In March, Abbott launched a molecular test on its m2000™ RealTime lab-based platform to detect COVID-19 pursuant to an Emergency Use Authorization (EUA) in the U.S. and CE Mark.

●

In March, Abbott also launched a molecular test to detect COVID-19 on its ID NOW™ rapid point-of-care platform in the U.S. pursuant to an EUA.

●

In April, Abbott launched an IgG (Immunoglobulin G) lab-based serology blood test on its ARCHITECT^® i1000SR and i2000SR^® laboratory instruments for the detection of an antibody to determine if someone was previously infected with the virus. The serology test was granted an EUA in the U.S. and CE Mark in April 2020.

●

In May, Abbott launched a lab-based serology blood test on its Alinity^® i system pursuant to an EUA in the U.S. and CE Mark.

●

In May, Abbott also launched a molecular test on its Alinity m system to detect COVID-19 pursuant to an EUA in the U.S. Abbott received CE Mark for this test in June 2020.

●

In June, Abbott launched a lateral flow COVID-19 rapid antibody test on its Panbio™ system in select countries. This serology test detects an antibody to determine if someone was previously infected with the virus.

●

In August, Abbott launched its AdviseDx SARS-CoV-2 IgM (Immunoglobulin M) lab-based serology test for use on its ARCHITECT and Alinity platforms pursuant to a CE Mark. Abbott was granted an EUA in the U.S. for this test in October 2020.

●

In August, Abbott launched its BinaxNOW™ COVID-19 Ag Card test, a portable, lateral flow rapid test to detect COVID-19 pursuant to an EUA in the U.S.

●

In September, Abbott launched its Panbio rapid antigen test to detect COVID-19 pursuant to a CE Mark. In October, Abbott received approval by the World Health Organization for emergency use listing for the Panbio antigen test.

During the first nine months of 2020, Abbott’s COVID-19 testing related sales totaled $1.533 billion, of which $881 million was generated in the third quarter of 2020.

Abbott is continually implementing business continuity plans in the face of the pandemic. Due to the critical nature of its products and services, Abbott was generally exempt from governmental orders issued during the first quarter of 2020 in the U.S. and other countries requiring businesses to cease operations. The majority of its office-based work was conducted remotely during the period of such governmental orders and the company implemented strict travel restrictions. As some governmental orders were lifted in May and June 2020, Abbott entered a new phase in its operations whereby some office-based employees started working at Abbott’s offices on a rotational basis. Abbott has taken aggressive steps to limit exposure and enhance the safety of facilities for its employees.

With respect to Abbott’s financial position, at September 30, 2020, Abbott’s cash and cash equivalents and short-term investments totaled approximately $4.7 billion compared to $4.1 billion at December 31, 2019. Existing credit agreements are in place that would provide additional access to $5 billion, if needed.

Due to the unpredictability of the duration and impact of the current COVID-19 pandemic, the extent to which the COVID-19 pandemic may have a material effect on its business, financial condition or results of operations is uncertain.

Table of Contents

The following table details sales by reportable segment for the three ~~months~~ and nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.


	Net Sales to External Customers										Net Sales to External Customers
	Three Months		Three Months								Three Months		Three Months
	Ended		Ended				Impact of		Total Change		Ended		Ended				Impact of		Total Change
	September 30,		September 30,		Total		Foreign		Excl. Foreign		September 30,		September 30,		Total		Foreign		Excl. Foreign
(in millions)	2019		2018		Change		Exchange		Exchange		2020		2019		Change		Exchange		Exchange

Established Pharmaceutical Products	$	1,212	$	1,159	4.4	%	(3.5)	%	7.9	%	$	1,099	$	1,212	(9.3)	%	(6.0)	%	(3.3)	%
Nutritional Products		1,874		1,838	2.0		(1.3)		3.3			1,924		1,874	2.6		(1.5)		4.1
Diagnostic Products		1,909		1,824	4.7		(1.9)		6.6			2,640		1,909	38.2		(0.6)		38.8
Cardiovascular and Neuromodulation Products		2,400		2,303	4.2		(1.4)		5.6
Medical Devices												3,170		3,065	3.4		0.8		2.6
Total Reportable Segments		7,395		7,124	3.8		(1.8)		5.6			8,833		8,060	9.6		(1.0)		10.6
Other		681		532	28.0		(3.5)		31.5			20		16	23.1		1.1		22.0
Net Sales	$	8,076	$	7,656	5.5		(1.9)		7.4		$	8,853	$	8,076	9.6		(1.0)		10.6

Total U.S.	$	2,834	$	2,707	4.7		—		4.7		$	3,329	$	2,834	17.4		—		17.4

Total International	$	5,242	$	4,949	5.9		(3.0)		8.9		$	5,524	$	5,242	5.4		(1.6)		7.0


	Net Sales to External Customers										Net Sales to External Customers
	Nine Months		Nine Months								Nine Months		Nine Months
	Ended		Ended				Impact of		Total Change		Ended		Ended				Impact of		Total Change
	September 30,		September 30,		Total		Foreign		Excl. Foreign		September 30,		September 30,		Total		Foreign		Excl. Foreign
(in millions)	2019		2018		Change		Exchange		Exchange		2020		2019		Change		Exchange		Exchange

Established Pharmaceutical Products	$	3,312	$	3,332	(0.6)	%	(7.1)	%	6.5	%	$	3,156	$	3,312	(4.7)	%	(6.0)	%	1.3	%
Nutritional Products		5,541		5,452	1.6		(2.8)		4.4			5,711		5,541	3.1		(1.7)		4.8
Diagnostic Products		5,655		5,534	2.2		(3.5)		5.7			6,460		5,655	14.2		(1.5)		15.7
Cardiovascular and Neuromodulation Products		7,202		7,047	2.2		(2.8)		5.0
Medical Devices												8,530		9,035	(5.6)		(0.6)		(5.0)
Total Reportable Segments		21,710		21,365	1.6		(3.7)		5.3			23,857		23,543	1.3		(1.9)		3.2
Other		1,880		1,448	29.9		(5.7)		35.6			50		47	6.1		(0.2)		6.3
Net Sales	$	23,590	$	22,813	3.4		(3.8)		7.2		$	23,907	$	23,590	1.3		(1.9)		3.2

Total U.S.	$	8,438	$	8,084	4.4		—		4.4		$	8,823	$	8,438	4.6		—		4.6

Total International	$	15,152	$	14,729	2.9		(5.8)		8.7		$	15,084	$	15,152	(0.4)		(2.8)		2.4

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

~~Net~~The 10.6 percent increase in total net sales ~~growth~~ in ~~2019,~~the third quarter of 2020, excluding the impact of foreign exchange, was primarily driven by ~~growth in all of Abbott’s reportable segments. The~~an increase in the ~~Other category reflects growth in~~Diagnostics segment as a result of demand for Abbott’s ~~Diabetes Care business where sales in the first nine months~~portfolio of ~~2019 increased 30.6 percent in total~~COVID-19 diagnostics tests on its lab-based immunoassay and ~~36.5 percent, excluding the effects of foreign exchange, to $1.833 billion. The Diabetes Care sales growth was led by FreeStyle Libre~~^®~~, Abbott’s continuous glucose monitoring system with worldwide sales of $1.308 billion, which reflected an increase versus the prior year of 65.4 percent in total~~molecular diagnostics systems and ~~72.9 percent, excluding the effects of foreign exchange.~~

~~Table of Contents~~

~~Excluding the impact of foreign exchange, total net sales increased 7.4 percent in the third quarter of 2019 and 7.2 percent in the first nine months of 2019.~~point-of-care rapid testing platforms. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates during the period compared to ~~2018. The relatively stronger U.S. dollar decreased total international sales by 3.0 percent and total sales by 1.9 percent in~~ the third quarter of 2019. The relatively stronger U.S. dollar decreased total international sales by ~~5.8~~1.6 percent and total sales by ~~3.8~~1.0 percent in the third quarter of 2020.

The 3.2 percent increase in total net sales during the first nine months of 2020, excluding the impact of foreign exchange, was driven by increases in the Diagnostics and Nutritional Products segments, partially offset by a decrease in the Medical Devices segment due to reduced procedure volumes as a result of the pandemic. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first nine months of ~~2019.~~2020 as the relatively stronger U.S. dollar decreased total international sales by 2.8 percent and total sales by 1.9 percent.

Table of Contents

The table below provides detail by sales category for the nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.

Impact of

Total Change

September 30,

September 30,

Total

Foreign

Excl. Foreign

(in millions)

2019

2018

Change

Exchange

Exchange

Established Pharmaceutical Products —











Key Emerging Markets

$
2,496

$
2,525

(1.2)
%
(8.6)
%
7.4
%
Other Emerging Markets

816

807

1.0

(2.7)

3.7

Nutritionals —











International Pediatric Nutritionals

1,718

1,708

0.6

(4.2)

4.8

U.S. Pediatric Nutritionals

1,406

1,376

2.2

—

2.2

International Adult Nutritionals

1,502

1,431

4.9

(5.7)

10.6

U.S. Adult Nutritionals

915

937

(2.4)

—

(2.4)

Diagnostics —











Core Laboratory

3,407

3,233

5.4

(4.6)

10.0

Molecular

326

361

(9.5)

(2.5)

(7.0)

Point of Care

424

416

2.1

(0.5)

2.6

Rapid Diagnostics

1,498

1,524

(1.7)

(2.3)

0.6

Cardiovascular and Neuromodulation —











Rhythm Management

1,600

1,667

(4.0)

(2.8)

(1.2)

Electrophysiology

1,262

1,144

10.3

(2.8)

13.1

Heart Failure

571

468

22.0

(1.5)

23.5

Vascular (a)

2,136

2,209

(3.3)

(3.0)

(0.3)

Structural Heart

1,024

913

12.1

(3.8)

15.9

Neuromodulation

609

646

(5.7)

(1.4)

(4.3)

(a) Vascular Product Lines:

Coronary and Endovascular

2,049

2,085

(1.7)

(3.1)

1.4


							Impact of		Total Change
	September 30,		September 30,		Total		Foreign		Excl. Foreign
(in millions)	2020		2019		Change		Exchange		Exchange
Established Pharmaceutical Products —
Key Emerging Markets	$	2,376	$	2,496	(4.8)	%	(8.0)	%	3.2	%
Other Emerging Markets		780		816	(4.4)		(0.1)		(4.3)

Nutritionals —
International Pediatric Nutritionals		1,629		1,718	(5.2)		(2.5)		(2.7)
U.S. Pediatric Nutritionals		1,490		1,406	5.9		—		5.9
International Adult Nutritionals		1,644		1,502	9.5		(3.5)		13.0
U.S. Adult Nutritionals		948		915	3.7		—		3.7

Diagnostics —
Core Laboratory		3,152		3,407	(7.5)		(1.8)		(5.7)
Molecular		956		326	193.0		(3.2)		196.2
Point of Care		387		424	(8.8)		(0.3)		(8.5)
Rapid Diagnostics		1,965		1,498	31.1		(0.8)		31.9

Medical Devices —
Rhythm Management		1,382		1,600	(13.6)		(0.6)		(13.0)
Electrophysiology		1,128		1,262	(10.6)		(0.3)		(10.3)
Heart Failure		551		571	(3.5)		(0.2)		(3.3)
Vascular (a)		1,736		2,136	(18.7)		(0.6)		(18.1)
Structural Heart		894		1,024	(12.7)		(0.4)		(12.3)
Neuromodulation		489		609	(19.7)		(0.2)		(19.5)
Diabetes Care		2,350		1,833	28.2		(1.2)		29.4

(a) Vascular Product Lines:
Coronary and Endovascular		1,676		2,049	(18.2)		(0.7)		(17.5)

Key Emerging Markets for the Established Pharmaceutical Products business include India, Russia, Brazil and China, along with several other markets that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets increased ~~7.4~~3.2 percent compared to the first nine months of ~~2018~~2019 led primarily by growth in China and various countries in Asia and Latin America. The nine-month growth rate was negatively impacted by lower demand in the second and third quarters of 2020 due to ~~growth~~the spread of COVID-19 across ~~several geographies including India, Russia, China and Brazil. Excluding~~emerging market countries. Other Emerging Markets, excluding the ~~unfavorable~~ effect of foreign exchange, ~~sales in Other Emerging Markets increased 3.7~~decreased by 4.3 percent ~~compared to the first nine months of 2018. Sales growth in Other Emerging Markets was negatively impacted~~ in the first nine months of ~~2019 by the discontinuation of a non-core, low-margin agreement under which Abbott supplied product to a third party.~~2020.

~~The 4.8 percent increase in~~ International Pediatric Nutritional sales, excluding the effect of foreign exchange, ~~was driven by growth~~decreased 2.7 percent in the first nine months of 2020 versus the comparable 2019 period. Growth across Abbott’s pediatric products in various countries in Southeast Asia ~~and Latin America across Abbott’s portfolio, including PediaSure~~^® ~~and Pedialyte~~^®~~. This growth~~ was ~~partially~~more than offset by challenging market dynamics in the Greater China infant category. ~~In the~~ U.S.~~, the 2.2 percent increase in~~ Pediatric Nutritional sales ~~reflects growth in~~increased 5.9 percent primarily due to increased demand for Pedialyte^®, Abbott’s oral rehydration brand, and ~~PediaSure.~~Pediasure^®. The ~~10.6~~13.0 percent increase in International Adult Nutritional sales, excluding the effect of foreign exchange, reflects continued growth of the Ensure^® and Glucerna^® brands in several countries. ~~In the~~ U.S. Adult Nutritional ~~business, the decline reflects Abbott’s discontinuation of a non-core product line during the third quarter of 2018.~~sales increased 3.7 percent due to growth in Ensure.

~~The~~In the Diagnostics segment, Core Laboratory sales decreased 5.7 percent, ~~increase in Diagnostic Products sales,~~ excluding the effect of foreign exchange, as the lower volume of routine testing performed in hospital and other laboratories due to COVID-19 was ~~driven~~partially offset by ~~above-market growth in~~sales of Abbott’s COVID-19 laboratory-based tests for the detection of the IgG and IgM antibodies, which determine if someone was previously infected with the virus. Core Laboratory antibody testing-related sales on Abbott’s ARCHITECT and Alinity i platforms were $212 million in the ~~U.S., and internationally where Abbott is achieving continued adoption~~first nine months of ~~its Alinity~~^® ~~family of diagnostic instruments. In July 2019, Abbott received U.S. Food and Drug Administration (FDA) approval for its Alinity blood and plasma screening system.~~2020. The ~~7.0~~196.2 percent ~~decrease~~increase in Molecular Diagnostics sales, excluding the effect of foreign exchange, reflects higher volumes due to demand for Abbott’s laboratory-based molecular tests for COVID-19 on its m2000 and Alinity m platforms. Molecular Diagnostics COVID-19 testing-related sales were $672 million in the ~~negative~~first nine months of 2020.

In Rapid Diagnostics, sales increased 31.9 percent, excluding the effect of foreign exchange, due to strong demand for Abbott’s point-of-care COVID-19 molecular test on its ID NOW platform and its BinaxNOW COVID-19 Ag Card test in the U.S. as well as international demand for COVID-19 rapid tests on its Panbio system and increased testing in the first quarter for the flu in the U.S. These increases were partially offset by the unfavorable impact of ~~lower non-governmental organization purchases~~COVID-19 on routine diagnostic testing. Rapid Diagnostics COVID-19 testing-related sales were $649 million in ~~Africa.~~ the first nine months of 2020.

Excluding the effect of foreign exchange, total Medical Devices sales decreased 5.0 percent; the decrease was driven by the impact of COVID-19 on Abbott’s cardiovascular and neuromodulation businesses, partially offset by double-digit growth in Diabetes Care. Growth in Diabetes Care sales was driven by continued growth of FreeStyle Libre^®, Abbott’s continuous glucose monitoring system, internationally and in the U.S. FreeStyle Libre sales totaled $1.880 billion in the first nine months of 2020, which reflected a 44.8 percent increase, excluding the effect of foreign exchange, over the first nine months of 2019 when FreeStyle Libre sales totaled $1.308 billion.

In ~~March 2019,~~June, Abbott announced ~~that it~~U.S. Food and Drug Administration (FDA) clearance of FreeStyle Libre 2 as an integrated continuous glucose monitoring (iCGM) system for adults and children ages 4 and older with diabetes. In September, Abbott obtained CE Mark for its ~~Alinity molecular diagnostics~~FreeStyle Libre 3 system, which automatically delivers real time, up-to-the-minute glucose readings, 14-day accuracy and ~~several testing assays. In Rapid Diagnostics, sales growth~~real-time glucose alarms. Abbott also obtained CE Mark for its Libre Sense™ Glucose Sport Biosensor in ~~several areas, including cardio-metabolic testing, was mostly offset by lower than expected infectious disease testing sales in Africa.~~

Europe. Libre Sense is a consumer over-the-counter product that provides continuous glucose monitoring for athletes to better understand the efficacy of their nutrition choices on training and athletic performance.

2220

Table of Contents

~~Excluding~~

In Abbott’s cardiovascular and neuromodulation businesses, revenues during the ~~effect~~first nine months of ~~foreign exchange, total Cardiovascular~~2020 were negatively impacted by reduced procedure volumes due to COVID-19. Procedure volume trends improved over the course of the second and ~~Neuromodulation Products sales grew 5.0 percent;~~third quarters as both demand for procedures and availability of healthcare resources return to more normal levels. In April, Abbott announced CE Mark approval for its TriClip^® heart valve repair system, the increase was driven by double-digit growth in Electrophysiology, Heart Failure and Structural Heart. The growth in Electrophysiology reflects higher sales of cardiac diagnostic and ablation catheters in both the U.S. and internationally.world’s first minimally invasive, clip-based tricuspid heart valve repair device. In ~~January 2019,~~July, Abbott announced U.S. FDA approval of its ~~TactiCath~~next-generation Gallant™ implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices to help manage heart rhythm disorders. These devices offer Bluetooth technology and a new patient smartphone app for improved remote monitoring and enhanced patient-physician engagement. In September, Abbott obtained CE Mark for MitraClip^® ~~contact force ablation catheter, Sensor Enabled™, which is designed to help physicians treat atrial fibrillation, a form of irregular heartbeat.~~G4, its next-generation MitraClip mitral valve repair device.

In ~~Heart Failure, growth~~April 2017, Abbott received a warning letter from the U.S. FDA related to its manufacturing facility in Sylmar, CA which was ~~driven~~acquired by ~~rapid market adoption~~Abbott on January 4, 2017 as part of the acquisition of St. Jude Medical. This facility manufactures implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and monitors. Abbott prepared and executed a comprehensive plan of corrective actions. On April 28, 2020, Abbott received a letter from the FDA indicating that, based on the FDA’s evaluation, it appeared that Abbott had addressed the items in the ~~U.S.of Abbott’s HeartMate 3~~^® Left Ventricular Assist Device following FDA approval in October 2018 as a destination (long-term use) therapy for people living with advanced heart failure. In March 2019, Abbott announced new data from its MOMENTUM 3 clinical study, the largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure, which demonstrated HeartMate 3 improved survival and clinical outcomes in this patient population.

~~Growth in Structural Heart was broad-based across several areas of the business, including MitraClip~~^®, Abbott's market-leading device for the minimally invasive treatment of mitral regurgitation (MR), a leaky heart valve. During the first quarter of 2019, Abbott received U.S. FDA approval for a new, expanded indication for MitraClip to treat clinically significant secondary MR aswarning letter. As a result, ~~of underlying heart failure. This new indication expands~~ the number of people with MR that can be treated with the MitraClip device. In July 2019, Abbott received U.S. FDA approval of the next generation of its MitraClip device, which includes a new leaflet grasping enhancement, an expanded range of clip sizes and facilitation of procedure assessment in real time to offer doctors further options when treating mitral valve disease.

In Vascular, excluding the effect of foreign exchange, revenues were basically flat as the 1.4 percent increase in coronary and endovascular product sales, which includes drug-eluting stents, balloon catheters, guidewires, vascular imaging/diagnostics products, vessel closure, carotid and other coronary and peripheral products, was offset primarily by a reduction in royalty revenue. In Rhythm Management, the 1.2 percent decline in revenues, excluding the effect of foreign exchange, reflects a 6.3 percent decrease in U.S. sales partially offset by a 4.0 percent increase in international sales. The 4.3 percent decline in Neuromodulation sales, excluding the effect of foreign exchange, reflects a 5.4 percent decline in U.S. sales.warning letter is considered closed.

The gross profit margin percentage was 49.4 percent for the third quarter of 2020 compared to 52.4 percent for the third quarter of ~~2019 compared to 51.5 percent for the third quarter of 2018.~~2019. The gross profit margin percentage was 49.2 percent for the first nine months of 2020 compared to 52.3 percent for the first nine months of ~~2019 compared~~2019. The decreases in the gross profit margin percentage primarily reflect the mix of sales across Abbott’s various businesses and operational inefficiencies due to ~~50.9 percent for~~ the ~~first nine months~~impact of ~~2018. The~~COVID-19, as well as the increase in intangible asset amortization, the ~~first nine months~~impairment of ~~2019 primarily reflects~~an intangible asset and the ~~favorable comparison versus the prior year from lower intangible amortization expense, and integration and restructuring costs~~unfavorable effect of foreign exchange on gross margin in ~~2019.~~2020.

Research and development (R&D) expenses ~~increased by $22~~decreased $16 million, or ~~3.7~~2.8 percent, in the third quarter of ~~2019~~2020 and ~~increased by $107~~decreased $123 million, or ~~6.1~~6.7 percent, in the first nine months of ~~2019~~2020 compared to the prior year. The ~~increase~~decrease in the third quarter of ~~2019~~2020 primarily reflects ~~higher~~lower integration and restructuring costs in 2020 related to R~~&D spending in various businesses and the acquisition of an R&D asset.~~&D. The ~~increase~~decrease in R&D spending in the first nine months of ~~2019~~2020 primarily reflects ~~higher spending on~~ the ~~acquisition of R&D assets. In~~immediate expensing in the first quarter of 2019 of an R&D asset valued at $102 million in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired an R&D asset valued at $102 million, which was immediately expensed. During the first nine months of 2018, Abbott acquired R&D assets valued at $43 million, which were immediately expensed. The ~~increase~~decrease in R&D expense during the first nine months of ~~2019 was~~2020 also ~~driven by higher R&D spending in various businesses, including Cardiovascular and Neuromodulation, partially offset by~~reflects the favorable effect of foreign ~~exchange.~~exchange in 2020. For the nine months ended September 30, ~~2019,~~2020, research and development expenditures totaled ~~$811~~$921 million for the ~~Cardiovascular and Neuromodulation Products~~Medical Devices segment, $419 million for the Diagnostic Products segment, ~~$142~~$137 million for the Nutritional Products segment and ~~$137~~$127 million for the Established Pharmaceutical Products segment.

Selling, general and administrative (SG&A) expenses ~~increased 2.7~~decreased 5.7 percent in the third quarter and decreased ~~0.4~~3.1 percent in the first nine months of ~~2019.~~2020. The ~~increase~~decreases in the quarter ~~is primarily~~and the first nine months of 2020 are due to ~~higher selling and marketing costs to drive continued growth across various businesses, partially offset by~~income of $100 million from a litigation settlement in 2020, the favorable effect of foreign exchange, lower spending due to COVID-19 mobility restrictions, and ~~lower acquisition-related integration costs. The decrease in~~ the ~~first nine months~~impact of ~~2019 is due primarily to the favorable effect of foreign exchange and lower acquisition-related integration costs,~~various cost saving initiatives, partially offset by higher ~~selling and marketing costs~~spending to drive ~~continued~~ growth ~~across~~in various businesses.

Restructuring Plans

The results for the first nine months of ~~2019~~2020 reflect charges under approved restructuring plans as part of the integration of the acquisitions of St. Jude Medical and Alere or as part of various cost reduction programs. Abbott recorded employee related severance and other charges of ~~$101~~$42 million in the first nine months of ~~2019~~2020 related to these initiatives, of which ~~$28~~$7 million is recognized in Cost of products sold, ~~$12~~$2 million is recognized in Research and development and ~~$61~~$33 million is recognized in SG~~&A expense.~~&A. See Note 7 to the financial statements, “Restructuring Plans,” for additional information regarding these charges.

~~Table of Contents~~

Other (Income) Expense, net

Other (income) expense, net totaled ~~$55~~$46 million of income in the third quarter of ~~2019~~2020 compared to ~~$18~~$55 million of ~~expense~~income in ~~2018~~2019 and ~~$140~~$25 million of income in the first nine months of ~~2019~~2020 compared to ~~$93~~$140 million of income in ~~2018.~~2019. The change in Other (income) expense, net infor the ~~third quarter~~first nine months of ~~2019 as compared to 2018 was~~2020 primarily ~~due to the recording of an impairment of an~~reflects equity investment ~~in 2018. The increase in Other (income) expense, net~~impairments that totaled approximately $110 million in the first nine months of 2019 compared to 2018 was due to higher 2019 income related to the non-service cost component of the net periodic benefit associated with Abbott’s pension and post-retirement benefit plans and the 2018 investment impairment, partially offset by an unrealized gain on an investment in 2018 that resulted from an observable price change for a similar investment of the same issuer.2020.

Interest Expense, net

Interest expense, net decreased ~~$38~~$16 million in the third quarter of ~~2019~~2020 and ~~$132~~$64 million in the first nine months of ~~2019~~2020 due to a reduction in interest expense resulting from the favorable impact of the euro debt ~~refinancing~~financing in ~~September 2018, as well as~~November of 2019, the repayment of debt in ~~2018~~December 2019 and ~~the first quarter of 2019.~~a lower interest rate environment in 2020.

Taxes on Earnings from Continuing Operations

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease between ~~$185~~$70 million and ~~$430~~$410 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., ~~Abbott’s~~Abbott's federal income tax returns through 2016 are settled except for the federal income tax returns of the former Alere consolidated group which are settled through ~~2014 and the former St. Jude Medical consolidated group which are settled through 2013.~~2015.

Table of Contents

Liquidity and Capital Resources September 30, ~~2019~~2020 Compared with December 31, ~~2018~~2019

On September 28, 2020, Abbott repaid the €1.140 billion outstanding principal amount of its 0.00% Notes due 2020 upon maturity. The debt repayment, which equated to approximately $1.3 billion, was primarily funded by the net proceeds from the issuance on June 24, 2020 of $1.3 billion aggregate principal amount of senior notes. The June 2020 issuance consisted of $650 million of 1.15% Notes due 2028 and $650 million of 1.40% Notes due 2030.

The ~~$247~~$620 million increase in cash and cash equivalents from ~~$3.8~~$3.9 billion at December 31, ~~2018~~2019 to ~~$4.1~~$4.5 billion at September 30, ~~2019~~2020 primarily reflects the favorable impact of cash generated by operating activities, partially offset by the payment of dividends and capital ~~expenditures and the repayment of approximately $500 million of debt in the first nine months of 2019.~~expenditures. Working capital was ~~$5.6~~$7.1 billion at September 30, ~~2019~~2020 and $4.8 billion at December 31, ~~2018. In 2019, increases~~2019. The $2.3 billion increase was due in ~~inventory, accounts receivable and~~large part to the higher level of cash and cash equivalents ~~were offset by~~noted above, as well as an increase in ~~the current portion of long-term debt~~inventory related to ~~debt that will mature in September 2020.~~shifting demand dynamics and higher accounts receivable balances due to higher levels of sales.

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first nine months of ~~2019~~2020 totaled ~~$3.7~~$4.1 billion, ~~a decrease~~an increase of ~~$815~~$383 million over the prior year due primarily to lower payments related to integration expenses, restructuring actions and interest, the proceeds from a litigation settlement payment and timing for various accrued expenses, partially offset by an increased investment in working ~~capital, higher~~capital. Other, net in Net cash ~~taxes paid~~from operating activities for the first nine months of 2020 was a source of $42 million and includes the impact of non-cash impairment charges related to intangible assets and equity investments and the payment timing ~~of pension contributions in 2019 relative to 2017 and 2018,~~for various accrued expenses partially offset by ~~higher operating earnings.~~the impact of the payment of cash taxes of approximately $700 million and $350 million of pension contributions. Other, net in Net cash from operating activities for the first nine months of 2019 was a use of $523 million and includes the ~~impact of the~~ payment of cash taxes of approximately $775 million and $337 million of pension contributions, partially offset by payment timing for various accrued expenses. Other, net in Net cash from operating activities for the first nine months of 2018 of $608 million includes the favorable impact of improvements in working capital management, as well as the effect of non-cash charges related to the impairment of certain assets and the accrual of certain debt extinguishment costs. Other, net in Net cash from operating activities for the first nine months of 2018 also includes $71 million of pension contributions as a pension contribution of $270 million was made in December 2017. Abbott expects to fund cash dividends, capital expenditures and its other investments in its businesses with cash flow from operating activities, cash on hand, short-term investments and borrowings.

~~Table of Contents~~

In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. This bond redemption authorization ~~supersedes~~superseded the board’s previous authorization under which $700 million had not yet been redeemed. In December 2019, Abbott redeemed $2.850 billion of debt. After this redemption, $2.15 billion of the $5 billion debt redemption authorization remains available.

At September 30, ~~2019,~~2020, Abbott’s long-term debt rating was ~~BBB+~~A- by Standard & Poor’s Corporation and A3 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2023.

In October 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott’s common shares from time to time. ~~The new~~This authorization is in addition to the ~~$795~~$270 million unused portion of the ~~previous~~ share repurchase program ~~that was~~ authorized in ~~September~~ 2014.

On April 27, 2016, the board of directors authorized the issuance and sale for general corporate purposes of up to 75 million common shares that would result in proceeds of up to $3 ~~billion of common shares for general corporate purposes.~~billion. No shares have been issued under this authorization.

In each of the first three quarters of ~~2019,~~2020, Abbott declared a quarterly dividend of ~~$0.32~~$0.36 per share on its common shares, which represents an increase of approximately 1412.5 percent over the ~~$0.28~~$0.32 per share quarterly dividend declared in each of the first three quarters of ~~2018.~~2019.

Recently ~~Issued~~Adopted Accounting Standards ~~Not Yet Adopted~~

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. The new standard will be effective for Abbott at the beginning of 2020, with early adoption permitted. Abbott is currently assessing the impact of this new standard on its consolidated financial statements.

~~Lease Accounting Standard~~

~~In February 2016, the FASB issued ASU 2016-02,~~ ~~Leases~~~~, which requires lessees to measure and recognize a lease asset and liability on the balance sheet for most leases, including operating leases.~~ Abbott adopted the ~~new~~ standard ~~as of~~on January 1, ~~2019 using the modified retrospective approach~~2020 and ~~applied the standard’s transition provisions as of January 1, 2019. As~~recorded a ~~result, no changes were made~~cumulative adjustment that was not significant to the December 31, 2018 Consolidated Balance Sheet. Abbott elected to apply the package of practical expedients related to transition. These practical expedients allowed Abbott to carry forward its historical assessments of whether any existing contracts are or contain leases, the lease classification for each lease existing at January 1, 2019, and whether any initial direct costs for such leases qualified for capitalization.

~~The new lease accounting standard does not have a material impact on the amounts reported~~Earnings employed in the ~~Condensed Consolidated Statement of Earnings but does have a material impact on the amounts reported~~business in the Condensed Consolidated Balance Sheet. ~~Adoption~~

Recently Issued Accounting Standards Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first quarter of 2021 and early adoption is permitted. Abbott does not expect adoption of this new standard ~~resulted in the recording of approximately $850 million of new right of use (ROU) assets and additional liabilities for operating leases~~to have a material impact on ~~the Condensed Consolidated Balance Sheet as of January 1, 2019.~~its condensed consolidated financial statements.

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the ~~2018~~2019 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions ~~investors~~ that any forward-looking statements ~~or projections~~ made by Abbott ~~including those made in this document,~~ are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott's operations and financial results, that may cause actual results to differ materially from those ~~projected.~~indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect ~~Abbott’s~~Abbott's operations are discussed in Item 1A, ~~Risk Factors,~~"Risk Factors'', in the ~~2018~~2019 Annual Report on Form ~~10-K.~~10-K and in Item 1A, “Risk Factors”, in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

2522

Table of Contents

PART I. FINANCIAL INFORMATION

Item 4.Controls and Procedures

~~(a)~~~~Evaluation of disclosure controls and procedures.~~ The Chief Executive Officer, Miles D. White, and Chief Financial Officer, Brian B. Yoor, evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(a)

Evaluation of disclosure controls and procedures. The President and Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

~~(b)~~~~Changes in internal control over financial reporting.~~ During the quarter ended September 30, 2019, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

(b)

Changes in internal control over financial reporting. During the quarter ended September 30, 2020, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, including those described in our Annual Report on Form 10-K for the year ended December 31, ~~2018.~~2019.

~~Table of Contents~~

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c)Issuer Purchases of Equity Securities

(d) Maximum

Number (or

(c) Total Number

Approximate

(c) Total Number

Approximate

of Shares (or

Dollar Value) of

of Shares (or

Dollar Value) of

(a) Total

Units) Purchased

Shares (or Units)

(a) Total

Units) Purchased

Shares (or Units)

Number of

(b) Average

as Part of

that May Yet Be

Number of

(b) Average

as Part of

that May Yet Be

Shares (or

Price Paid per

Publicly

Purchased Under

Shares (or

Price Paid per

Publicly

Purchased Under

Units)

Share (or

Announced Plans

the Plans or

Units)

Share (or

Announced Plans

the Plans or

Period

Purchased

Unit)

or Programs

Programs

Purchased

Unit)

or Programs

Programs

July 1, 2019 - July 31, 2019

294

⁽¹⁾

88.740

795,235,049

⁽²⁾

August 1, 2019 - August 31, 2019

28,134

⁽¹⁾

85.134

795,235,049

⁽²⁾

September 1, 2019 - September 30, 2019

11,800

⁽¹⁾

83.354

795,235,049

⁽²⁾

July 1, 2020 - July 31, 2020

⁽¹⁾

3,270,234,923

⁽²⁾

August 1, 2020 - August 31, 2020

⁽¹⁾

3,270,234,923

⁽²⁾

September 1, 2020 - September 30, 2020

28,423

⁽¹⁾

109.47

3,270,234,923

⁽²⁾

Total

40,228

⁽¹⁾

84.638

795,235,049

⁽²⁾

28,423

⁽¹⁾

109.47

3,270,234,923

⁽²⁾

1.	~~These shares include:~~

1. These shares include the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options – 0 in July, 0 in August, and 28,423 in September.

~~(i)~~

~~the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options – 294 in July, 16,334 in August, and 0 in September; and~~

~~(ii)~~

~~the shares purchased on the open market for the benefit of participants in the Abbott Laboratories, Limited Employee Stock Purchase Plan – 0 in July, 11,800 in August, and 11,800 in September.~~

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

On September 11, 2014, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2014 Plan”). On October 11, 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2019 Plan”). The 2019 Plan is in addition to the unused portion of the 2014 Plan.

2. On September 11, 2014, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2014 Plan”). On October 11, 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2019 Plan”). The 2019 Plan is in addition to the unused portion of the 2014 Plan.

2723

Table of Contents

Item 6. Exhibits


Exhibit No.		Exhibit

~~3.1~~		~~By-Laws of Abbott Laboratories, as amended and restated effective September 9, 2019, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K filed on September 10, 2019.~~

31.1		Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

31.2		Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and nine months ended September 30, ~~2019,~~2020, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of ~~Shareholders'~~Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.

104		Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).

2824

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


ABBOTT LABORATORIES


By:	/s/ ~~Brian B. Yoor~~Robert E. Funck, Jr.
	~~Brian B. Yoor~~Robert E. Funck, Jr.
	Executive Vice President, Finance and Chief Financial Officer

	Date: ~~October 31, 2019~~November 4, 2020

2925


	Three Months Ended September 30, 2019						Three Months Ended September 30, 2018
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	891	$	891	$	—	$	866	$	866
Other		—		321		321		—		293		293
Total		—		1,212		1,212		—		1,159		1,159

Nutritionals —
Pediatric Nutritionals		478		566		1,044		459		580		1,039
Adult Nutritionals		310		520		830		315		484		799
Total		788		1,086		1,874		774		1,064		1,838

Diagnostics —
Core Laboratory		272		905		1,177		249		837		1,086
Molecular		35		76		111		37		84		121
Point of Care		112		32		144		106		30		136
Rapid Diagnostics		283		194		477		274		207		481
Total		702		1,207		1,909		666		1,158		1,824

Cardiovascular and Neuromodulation —
Rhythm Management		265		273		538		272		261		533
Electrophysiology		185		242		427		169		212		381
Heart Failure		136		50		186		111		41		152
Vascular		251		446		697		284		436		720
Structural Heart		158		190		348		126		179		305
Neuromodulation		165		39		204		172		40		212
Total		1,160		1,240		2,400		1,134		1,169		2,303

Other		184		497		681		133		399		532
Total	$	2,834	$	5,242	$	8,076	$	2,707	$	4,949	$	7,656


	Nine Months Ended September 30, 2019						Nine Months Ended September 30, 2018
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	2,496	$	2,496	$	—	$	2,525	$	2,525
Other		—		816		816		—		807		807
Total		—		3,312		3,312		—		3,332		3,332

Nutritionals —
Pediatric Nutritionals		1,406		1,718		3,124		1,376		1,708		3,084
Adult Nutritionals		915		1,502		2,417		937		1,431		2,368
Total		2,321		3,220		5,541		2,313		3,139		5,452

Diagnostics —
Core Laboratory		793		2,614		3,407		725		2,508		3,233
Molecular		113		213		326		114		247		361
Point of Care		334		90		424		324		92		416
Rapid Diagnostics		881		617		1,498		855		669		1,524
Total		2,121		3,534		5,655		2,018		3,516		5,534

Cardiovascular and Neuromodulation —
Rhythm Management		790		810		1,600		843		824		1,667
Electrophysiology		549		713		1,262		499		645		1,144
Heart Failure		428		143		571		342		126		468
Vascular		787		1,349		2,136		854		1,355		2,209
Structural Heart		446		578		1,024		353		560		913
Neuromodulation		485		124		609		513		133		646
Total		3,485		3,717		7,202		3,404		3,643		7,047

Other		511		1,369		1,880		349		1,099		1,448
Total	$	8,438	$	15,152	$	23,590	$	8,084	$	14,729	$	22,813


(in millions)
Contract Liabilities:
Balance at December 31, 2018	$	259
Unearned revenue from cash received during the period		285
Revenue recognized that was included in contract liability balance at beginning of period		(249)
Balance at September 30, 2019	$	295


	Three Months Ended		Nine Months Ended
(in millions)	September 30, 2019		September 30, 2019
Operating lease cost (a)	$	79	$	233
Cash paid for amounts included in the measurement of operating lease liabilities	$	64	$	190
ROU assets arising from entering into new operating lease obligations	$	104	$	201


(in millions)
2019	$	61
2020		225
2021		177
2022		137
2023		98
Thereafter		380
Total future minimum lease payments – undiscounted		1,078
Less: imputed interest		(174)
Present value of lease liabilities	$	904